NDA 019824 · Eurofarma
Loprox
Ciclopirox · Topical
Last checked: Nov 20, 2026Latest source record: Nov 4, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1988
Dec 30, 1988
Approved uses
1
Original approval plus efficacy supplements
Registered trials
17
4 Phase 3, 1 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 30, 1988 Original approval · Type 3 - New Dosage Form
1 products under this application
- LOPROX · CICLOPIROX 0.77% · SUSPENSION, TOPICAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Ciclopirox" as an intervention, any sponsor and status, largest first.
- Safety and Equivalence of a Generic Ciclopirox Olamine Cream Compared to the Reference Ciclopirox Cream 0.77% for the Treatment of Tinea PedisPivotal-lookingCompleted
Padagis LLCIndustry
NCT00802672 · 561 participants · Start Dec 2003 · Primary completion May 2004
Drug: Ciclopirox Olamine Cream; Loprox Cream 0.77% and 1 more · For: Tinea Pedis
- Safety and Equivalence of a Generic Ciclopirox Olamine Topical Suspension Compared to the Reference Ciclopirox Topical Suspension 0.77% for the Treatment of Tinea PedisPivotal-lookingCompleted
Padagis LLCIndustry
NCT00804193 · 553 participants · Start Jun 2004 · Primary completion Dec 2004
Drug: Ciclopirox Olamine Topical Suspension; Ciclopirox Topical Suspension 0.77%-Reference Product and 1 more · For: Tinea Pedis
- Study to Evaluate the Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)Pivotal-lookingCompleted
Moberg Pharma ABIndustry
NCT02866032 · 452 participants · Start Sep 2016 · Primary completion Jun 10, 2020
Drug: MOB015B; Ciclopirox 80 mg/g · For: Distal Subungual Onychomycosis
Sites: Multiple Locations, Germany; Multiple Locations, Poland; Multiple Locations, United Kingdom
- Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer in Dermatophytic OnychomycosisPivotal-lookingStatus unknown
Pierre Fabre Dermo CosmetiqueIndustry
NCT01014637 · 260 participants (planned) · Start Aug 2009 · Primary completion Sep 2011
Drug: Amorolfine (Antifungal); RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal) · For: Onychomycosis
Sites: Argenteuil, France; Brest, France; Cholet, France · 7 sites in all
- The Efficacy of CELEXT07 in the Treatment of Toenail OnychomycosisPivotal-lookingStatus unknown
9305-9954 Quebec IncIndustry
NCT02644551 · 120 participants (planned) · Start Nov 2016 · Primary completion May 2018
Drug: CELEXT07; Penlac · For: Onychomycosis
Sites: Montreal, Canada
- Tacrolimus Ointment Interest (PROTOPIC ®) in the Maintenance Treatment of Severe Seborrheic DermatitisPivotal-lookingCompleted
University Hospital, RouenAcademic, hospital or other
NCT02004860 · 120 participants · Start Jan 2014 · Primary completion Oct 2017
Drug: Protopic (R); Mycoster (R) · For: Severe Seborrheic Dermatitis
Sites: Rouen, France
Federal University of São PauloAcademic, hospital or other
NCT01139749 · 50 participants (planned) · Start Oct 2011 · Primary completion Jul 2012
Drug: oral isotretinoin; salicylic acid and ciclopirox olamine · For: Seborrhea; Seborrheic Dermatitis; Quality of Life
Sites: São Paulo, Brazil
Chen, Catherine, M.D.Academic, hospital or other
NCT00127868 · 47 participants · Start Mar 2005 · Primary completion Apr 2008
Drug: oral griseofulvin, selenium sulfide shampoo 1%, ciclopirox shampoo , ketoconazole shampoo 2%, baby shampoo · For: Tinea Capitis
Sites: Norfolk, Virginia
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Athlete's foot.
Crawford F · BMJ Clin Evid 2009 · Systematic Review
- Fungal toenail infections.
Ferrari J · BMJ Clin Evid 2014 · Systematic Review
- Fungal toenail infections.
Ferrari J · BMJ Clin Evid 2011 · Systematic Review
- Fungal toenail infections.
Ferrari J · BMJ Clin Evid 2008 · Systematic Review
- Athlete's foot.
Crawford F · BMJ Clin Evid 2006 · Systematic Review
- Seborrhoeic dermatitis of the scalp.
Naldi L, Diphoorn J · BMJ Clin Evid 2015 · Systematic Review
Sponsor: Eurofarma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.